Novartis Heart Failure Drug Patent Expiry - Impact on India

Posted On : January 15, 2023

Novartis’ heart failure drug to go off patent this month; Will this make cardiac care in India affordable?

Blog Banner
The affordable versions of the blockbuster drug are expected to hit the market this month and reportedly reduce the cost of the therapy by nearly half. A blockbuster heart failure drug by Swiss pharma major Novartis is going off-patent in January this year. Several pharmaceutical industry experts told Financial that the patent loss of Vymada or Entresto is set to cause major disruptions in India’s cardiology sector. Read more here..

Category: News

Recent News and Announcements

Unlock the door to exceptional healthcare, book an appointment with SPARSH Hospital and let your journey to wellness begin.